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AID mis-targeting is poorly understood but contributes significantly to B cell genome instability.
Two newpapers inCell reveal that AIDmistargeting occurs primarily in gene bodies within a nuclear
microenvironment characterized by high levels of transcriptional activity, interconnected transcrip-
tional regulatory elements, and overlapping sense and antisense (convergent) transcription.During their development and function, B
lymphocytes face a daunting series of
challenges to genome integrity. Early in
development, they must withstand multi-
ple DNA double-strand breaks made by
the RAG1/RAG2 endonuclease during
assembly of immunoglobulin (Ig) heavy-
and light-chain genes. Subsequently,
activated B cells must deal with a bevy
of mutations and DNA strand breaks
triggered by the activation-induced
deaminase (AID) during the processes of
somatic hypermutation (SHM) and class
switch recombination (CSR). Mistakes
made during these reactions, including
the erroneous targeting of non-Ig genes
by RAG and AID, are the cause of many
of the mutations and chromosomal aber-
rations found in B cell malignancies (Alt
et al., 2013; Nussenzweig and Nussenz-
weig, 2010). Preventing mis-targeting of
AID is a particular challenge because, un-
like RAG, AID has no DNA-binding motif
demarcating its appropriate target sites.
It has proven difficult to explain why AID
targets certain non-Ig genes, but not
others—an issue of considerable impor-
tance because many erroneous AID tar-
gets are key B lineage regulators and
potent proto-oncogenes. Two papers in
this issue of Cell (Meng et al., 2014; Qian
et al., 2014) take a major step forward in
unraveling thismystery by linking AIDmis-
targeting to the process of convergent
transcription within domains of highly
interconnected transcriptional regulatory
elements.
AID initiates SHM and CSR by deami-
nating cytosine residues in single-
stranded DNA to yield uracil bases. The
resulting U:G mismatches are processed
into mutations (for SHM) or double-
stranded breaks (for CSR) via DNA repair1490 Cell 159, December 18, 2014 ª2014 Elspathways involving general base excision
repair factors, mismatch repair factors,
and error-prone DNA polymerases (Di
Noia and Neuberger, 2007). AID targets
are invariably transcribed, and AID inter-
acts with a number of components of
the transcription machinery, including
RNA polymerase II (Pol II), the Pol II stall-
ing factor Spt5, the single-strand DNA-
binding complex RPA, and the RNA
exosome. Such factors, acting in the
context of stalled Pol II, are thought to re-
cruit AID and create the single-stranded
DNA substrate required for its action
(Keim et al., 2013). Transcription per se,
however, does not provide a ready expla-
nation for why only certain transcribed
non-Ig genes are targeted by AID or why
Ig genes sustain mutations due to SHM
at far higher levels than non-Ig genes
(Storb, 2014). Attention has therefore
focused on a central role for Pol II stalling,
with CSR target regions (switch regions)
providing an example of DNA sequences
that favor the accumulation and stalling
of Pol II and deamination by AID (Keim
et al., 2013). It has remained a major chal-
lenge to understand the targeting prefer-
ences of AID elsewhere in the genome
and to determine whether and how Pol II
stalling might be involved.
Qian et al. andMeng et al. identified AID
off-target DNAdouble-strand break (DSB)
sites in the genome of activated B cells
and intersected these data with an exten-
sive array of epigenetic, nuclear archi-
tecture, and transcriptional data sets.
Remarkably, most of the AID off-targets
were found to lie within super-enhancers,
large arrays of enhancers that accumulate
high levels of activating histone marks,
transcription factors, and components
of the transcriptional machinery (Whyteevier Inc.et al., 2013). Most of the DSB sites were
found to lie within the region of overlap
between a super-enhancer and the body
of an active gene, but a small fraction fell
in extragenic enhancers, which were
themselves invariably transcribed. Qian
et al. also found that the vast majority of
AID-initiated lesions occurred near tran-
scription start sites that were linked by
long-distance interactions with multiple
other promoters and enhancers, forming
a ‘‘regulatory cluster.’’ Not all regulatory
clusters or super-enhancers contained
an AID off-target site, but those that did
tended to be particularly large and have
more ‘‘connectivity’’ (more linked pro-
moters and enhancers) (Qian et al.,
2014). Hence, the off-target activity of
AID occurs preferentially in a particular
nuclear microenvironment consisting
of transcriptionally active, topologically
highly interconnected, super-enhancer
domains.
Why were only certain genes in this
permissive nuclear microenvironment tar-
geted by AID, and why did AID attack
those genes in specific locations? Using
very deep global run-on sequencing
(GRO-seq) data, Meng et al. provide a
remarkable answer to these questions:
off-target AID-mediated DNA breaks
almost invariably localized to sites of
overlapping sense and antisense tran-
scription, referred to as convergent tran-
scription. Stronger super-enhancers and
higher levels of convergent transcription
correlated well with higher levels of
AID-mediated DSBs. Together, the data
of Meng et al. and Qian et al. lead to a
model (Figure 1) in which AID-vulnerable
sites in the genome are defined by the
intersection of: (1) strong transcriptional
activity (super-enhancers); (2) multiple
Figure 1. Targeting of AID Activity in the Genome by Super-Enhancers
(A) AID acts preferentially on non-immunoglobulin targets (‘‘off-targets’’) located in highly transcribed super-enhancer domains containing extensive looping
between promoters and enhancers (regulatory clusters, RC), located within one topologically associated domain (TAD). Within these regions, AID acts at areas of
convergent transcription where polymerases proceed in both directions generating sense- and anti-sense transcripts. These opposing polymerases collide and
stall and, with the help of factors such as Spt5, RPA, and the RNA exosome complex, recruit AID and make single-stranded DNA substrates available for AID.
(B) In immunoglobulin switch regions, special DNA properties (a G-rich nontranscribed strand and R loops) cause RNA polymerase II (Pol II) to stall and, together
with multiple protein factors, to recruit AID and ensure single-stranded DNA accessibility. Whether super-enhancer features or convergent transcription further
contribute to the targeting of AID activity to switch regions is unknown.
(C) Targeting of AID and somatic hypermutation to immunoglobulin V regions are strongly enhanced by immunoglobulin enhancers by an unknown mechanism.
Because mutations in germinal center B cells accumulate much more frequently in IgV region than in any AID off-target region, different/additional mechanisms
are likely to be involved. A role for convergent transcription has not been ruled out.interconnected transcriptional regulatory
elements (regulatory clusters); and (3)
strong convergent transcription, in which
normal sense transcription of the gene
overlaps with super-enhancer-derived
antisense eRNA transcription. As Meng
et al. point out, two RNA polymerases
proceeding in opposite directions can
collide and stall, thereby providing a
favorable environment for the action of
AID (Figure 1). Importantly, Qian et al.
and Meng et al. extended their findings
to human lymphomas, mouse germinal
center B cells, and even mouse embryo
fibroblasts. To a large extent, AID suscep-
tibility tracked closely with the shifting
landscapes of convergent transcription
and super-enhancers. The one exception
was AID-mediated deamination events
detected as pointmutations in repair-defi-
cient, hypermutating B cells, where the
correlations weakened somewhat, partic-
ularly for genes targeted at very low levelsby AID (only one-third of which displayed
convergent transcription [Meng et al.,
2014]). AID might therefore act at a low
frequency outside of the permissive nu-
clear microenvironment defined by Qian
et al. and Meng et al., a significant issue
given the large number of such potential
targets.
Substantial mechanistic questions and
puzzles remain for those hoping to un-
derstand the targeting and mis-targeting
of AID. The Pol II collision model is very
attractive but now needs to be rigor-
ously tested. How the clustering of
regulatory elements contributes to AID
action is not known; might this relate to
the finding that Ig enhancers work
together to target SHM (Buerstedde
et al., 2014)? Not all sites of convergent
transcription within super-enhancers are
targeted by AID, suggesting that addi-
tional mechanisms might be layered on
top of those uncovered by Meng et al.Cell 159, Deand Qian et al. Although the Ig loci are
found within super-enhancer regulatory
clusters (Qian et al., 2014), it is not
known whether convergent transcription
contributes to the preferential targeting
of AID to Ig variable regions (Meng
et al., 2014). Finally, a recent study
linked another unexpected transcrip-
tional phenomenon—divergent antisense
transcription upstream of transcription
start sites—to the mis-targeting of AID
(Pefanis et al., 2014). There appears to
be much still to learn about the relation-
ship between the antics of Pol II and
those of AID.REFERENCES
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Cancer cells have distinctive nutrient demands to fuel growth and proliferation, including the
disproportionate use of glucose, glutamine, and fatty acids. Comerford et al. and Mashimo et al.
now demonstrate that several types of cancer are avid consumers of acetate, which facilitates
macromolecular biosynthesis and histone modification.Metabolic pathways in cancer cells are
programmed to facilitate survival and pro-
liferation in the nonnative microenviron-
ment of a tumor. This involves changes
in both the way extracellular nutrients
are captured and how they are metabo-
lized. Historically, research efforts have
focused on the wiring of glucose meta-
bolism, owing to the seminal observations
of Warburg and to the dominant role
glucose plays in many basic biosynthetic
processes (Vander Heiden et al., 2009).
The importance of other fuel sources,
including glutamine, lipids, and protein,
have received more recent attention
upon realization that pathways governing
their metabolism are often driven by on-
cogenes. In this issue of Cell, new studies
from the McKnight and Tu (Comerford
et al., 2014) and Maher and Bachoo labs
(Mashimo et al., 2014) illustrate that a
variety of cancers are also capable of
capturing and metabolizing exogenous
acetate and that this represents a meta-
bolic adaptation that some tumors use
to facilitate growth.
Acetate, when ligated to coenzyme A
(acetyl-CoA), is among the most central
and dynamic metabolites in intermediary
metabolism (Figure 1). It can be gener-ated by the oxidation of glucose, gluta-
mine, or fatty acids; it is used to bio-
synthesize nucleotides, amino acids,
and both principle components of the
cell membrane in mammals (i.e., fatty
acids and cholesterol); and it contributes
to enzyme and gene regulation by
reversibly adding to nonhistone protein
and histone tails, respectively (Figure 1)
(Kaelin and McKnight, 2013). Indeed,
numerous studies have illustrated the
fundamental roles that acetyl-CoA regu-
lation plays in cell growth and prolifera-
tive processes (Wellen and Thompson,
2012). However, under oxygen limiting
conditions, as are often seen in the
microenvironment of a tumor, the ability
of a cell to make acetyl-CoA is severely
hampered. Intrigued by this conundrum,
and based on the mechanisms by which
yeast generate acetyl-CoA, Comerford
et al. (2014) explored the functional
relevance of the mammalian homologs
of the yeast enzymes that generate
acetyl-CoA. Mammals express three
isoforms of short-chain acyl-CoA
synthetases (ACSS) that convert acetate
and coenzyme-A into acetyl-CoA by
consuming ATP. Two of these are
localized in mitochondria (ACSS1 andACSS3), and one can access both the
nuclear and cytoplasmic space, ACSS2
(Watkins et al., 2007). Comerford et al.
(2014) find that knockdown of ACSS2,
but not the mitochondrial isoforms,
dramatically impairs the incorporation of
exogenously supplied acetate into lipids
and histone protein. These results illus-
trate that proliferating mammalian cells,
including cancer cells, can consume
and contribute acetate carbon to the
cellular pool of acetyl-CoA.
In a parallel study, Mashimo et al.
(2014) similarly find that exogenous ace-
tate is captured and metabolized, here
by human cancer cells grown in the brain
of mice. The authors examined acetate
metabolism in this context based on an
earlier observation that a significant pro-
portion of carbon in the acetyl-CoA pool
could not be accounted for by tracing
glucose and glutamine metabolism
(Marin-Valencia et al., 2012). By tracing
acetate carbon, Mashimo et al. (2014)
reveal that TCA cycle intermediates
consist of as much as 50% acetate-
derived carbon by mass. In contrast,
non-tumor-bearing brain incorporates
on the order of 10% acetate-derived car-
bon into TCA cycle intermediates. These
